PPA
ITCI

Parametric Portfolio Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parametric Portfolio Associates’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$16.5M Sell
269,677
-4,903
-2% -$255K 0.01% 1074
2021
Q4 		$14.4M Buy
274,580
+59,385
+28% +$2.49M 0.01% 1153
2021
Q3 		$8.02M Sell
215,195
-20,676
-9% -$719K ﹤0.01% 1506
2021
Q2 		$9.63M Buy
235,871
+119,017
+102% +$4.4M 0.01% 1424
2021
Q1 		$3.96M Buy
116,854
+3,530
+3% +$122K ﹤0.01% 2330
2020
Q4 		$3.6M Sell
113,324
-40,707
-26% -$1.07M ﹤0.01% 2293
2020
Q3 		$3.95M Buy
154,031
+32,305
+27% +$737K ﹤0.01% 2059
2020
Q2 		$3.13M Buy
121,726
+19,556
+19% +$396K ﹤0.01% 2209
2020
Q1 		$1.57M Buy
102,170
+50,491
+98% +$1.1M ﹤0.01% 2531
2019
Q4 		$1.77M Buy
51,679
+9,667
+23% +$116K ﹤0.01% 2766
2019
Q3 		$314K Sell
42,012
-9,821
-19% -$94.2K ﹤0.01% 3508
2019
Q2 		$673K Buy
51,833
+7,223
+16% +$92.6K ﹤0.01% 3242
2019
Q1 		$543K Buy
44,610
+28,501
+177% +$364K ﹤0.01% 3293
2018
Q4 		$183K Sell
16,109
-4,934
-23% -$79.7K ﹤0.01% 3679
2018
Q3 		$457K Buy
21,043
+331
+2% +$6.92K ﹤0.01% 3448
2018
Q2 		$366K Sell
20,712
-33,077
-61% -$672K ﹤0.01% 3476
2018
Q1 		$1.13M Buy
53,789
+34,419
+178% +$670K ﹤0.01% 2952
2017
Q4 		$280K Buy
19,370
+4,416
+30% +$68.2K ﹤0.01% 3602
2017
Q3 		$236K Buy
+14,954
New +$219K ﹤0.01% 3785
2017
Q2 		– Sell
-92,971
Closed -$1.51M – 4042
2017
Q1 		$1.51M Buy
92,971
+75,027
+418% +$1.09M ﹤0.01% 2630
2016
Q4 		$271K Sell
17,944
-10,096
-36% -$143K ﹤0.01% 3476
2016
Q3 		$427K Buy
28,040
+3,407
+14% +$138K ﹤0.01% 3243
2016
Q2 		$956K Buy
24,633
+14,870
+152% +$534K ﹤0.01% 2862
2016
Q1 		$271K Buy
9,763
+5,220
+115% +$174K ﹤0.01% 3642
2015
Q4 		$244K Buy
+4,543
New +$229K ﹤0.01% 3645

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Parametric Portfolio Associates's ITCI Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 1.8% in Q1 2022, selling an estimated $255K and leaving 269,677 shares worth $16.5M. The position accounts for 0.01% of the portfolio, ranked #1074.

Parametric Portfolio Associates first reported a position in ITCI in Q4 2015 and has held it in 25 quarters since. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Parametric Portfolio Associates held 269,677 shares of Intra-Cellular Therapies Inc. worth $16.5M as of Q1 2022.
  • Parametric Portfolio Associates sold 4,903 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $255K.
  • Intra-Cellular Therapies Inc. made up 0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1074 holding.
  • Parametric Portfolio Associates first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and has held it in 25 quarters since.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.